These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Kando JC; Shepski JC; Satterlee W; Patel JK; Reams SG; Green AI Ann Pharmacother; 1997 Nov; 31(11):1325-34. PubMed ID: 9391688 [TBL] [Abstract][Full Text] [Related]
6. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Fulton B; Goa KL Drugs; 1997 Feb; 53(2):281-98. PubMed ID: 9028746 [TBL] [Abstract][Full Text] [Related]
9. Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic. Mujica R; Weiden P Am J Psychiatry; 2001 Apr; 158(4):650-1. PubMed ID: 11282706 [No Abstract] [Full Text] [Related]
10. Use of olanzapine for elderly patients with psychotic disorders: a review. Madhusoodanan S; Sinha S; Brenner R; Gupta S; Bogunovic O Ann Clin Psychiatry; 2001 Dec; 13(4):201-13. PubMed ID: 11958362 [TBL] [Abstract][Full Text] [Related]
11. Adverse events related to olanzapine. Conley RR; Meltzer HY J Clin Psychiatry; 2000; 61 Suppl 8():26-9; discussion 30. PubMed ID: 10811240 [TBL] [Abstract][Full Text] [Related]
12. Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia. Gray R Ment Health Care; 1998 Feb; 1(6):193-4. PubMed ID: 9791411 [TBL] [Abstract][Full Text] [Related]
13. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Allan ER; Sison CE; Alpert M; Connolly B; Crichton J Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201 [TBL] [Abstract][Full Text] [Related]
14. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331 [TBL] [Abstract][Full Text] [Related]
16. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413 [TBL] [Abstract][Full Text] [Related]
17. Novel antipsychotics: comparison of weight gain liabilities. Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912 [TBL] [Abstract][Full Text] [Related]
18. Severe akathisia during olanzapine treatment of acute schizophrenia. Jauss M; Schröder J; Pantel J; Bachmann S; Gerdsen I; Mundt C Pharmacopsychiatry; 1998 Jul; 31(4):146-8. PubMed ID: 9754850 [TBL] [Abstract][Full Text] [Related]
19. [Atypical neuroleptics in child- and adolescent psychiatry]. Remschmidt H; Hennighausen K; Clement HW; Heiser P; Schulz E Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):45-57. PubMed ID: 10746298 [TBL] [Abstract][Full Text] [Related]
20. Olanzapine: keep an eye on this neuroleptic. Leblanc G Can Fam Physician; 2000 Aug; 46():1565-6, 1569. PubMed ID: 10955171 [No Abstract] [Full Text] [Related] [Next] [New Search]